Protein binding of nifedipine.

The pharmacokinetics of oral nifedipine--a population study. Br J Clin Pharmacol (1988) 0.97

Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol (1991) 0.82

Nifedipine kinetics in the rat and relationship between its serum concentrations and uterine and cardiovascular effects. Br J Pharmacol (1988) 0.81

Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy. Br J Clin Pharmacol (1989) 0.75

Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther (2010) 2.13

Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther (2007) 1.90

Temporal variations in trough serum theophylline concentrations at steady state. J Pharm Sci (1980) 1.74

Natural course in chronic pancreatitis. Pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease. Digestion (1993) 1.71

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006. Clin Pharmacol Ther (2007) 1.70

Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias. Circulation (1983) 1.57

Effect of FOY-305 (camostate) on severe acute pancreatitis in two experimental animal models. Gastroenterology (1989) 1.53

Fascin, an echinoid actin-bundling protein, is a homolog of the Drosophila singed gene product. Proc Natl Acad Sci U S A (1993) 1.49

Pancreolauryl test. Evaluation of a tubeless pancreatic function test in comparison with other indirect and direct tests for exocrine pancreatic function. Dig Dis Sci (1983) 1.46

Aminopropyl glass and its p-phenylene diisothiocyanate derivative, a new support in solid-phase Edman degradation of peptides and proteins. FEBS Lett (1973) 1.43

Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives. J Clin Pharmacol (2000) 1.43

A nested PCR method for the detection of Bacillus anthracis in environmental samples collected from former tannery sites. Microbiol Res (1995) 1.42

The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther (2001) 1.36

Dose-dependent elimination kinetics of theophylline. Clin Pharmacokinet (1980) 1.34

Bioequivalence of topical dermatological dosage forms--methods of evaluation of bioequivalence. Pharm Res (1998) 1.31

Time-gated transillumination of biological tissues and tissuelike phantoms. Appl Opt (1994) 1.30

Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem (2001) 1.29

What is clinical utility and why should we care? Clin Pharmacol Ther (2010) 1.27

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol (2006) 1.27

Cloning and expression of a murine fascin homolog from mouse brain. J Biol Chem (1995) 1.22

Vancomycin disposition: the importance of age. Clin Pharmacol Ther (1984) 1.22

Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22

When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective. Clin Pharmacol Ther (2009) 1.22

Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther (2012) 1.20

Evaluation of orally administered highly variable drugs and drug formulations. Pharm Res (1996) 1.17

When should treatment of acute experimental pancreatitis be started? The early phase of bile-induced acute pancreatitis. Res Exp Med (Berl) (1988) 1.14

Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther (2010) 1.12

Pancreolauryl and NBT-PABA tests. Are serum tests more practicable alternatives to urine tests in the diagnosis of exocrine pancreatic insufficiency? Gastroenterology (1986) 1.12

Multicellular stalk-like structures in Saccharomyces cerevisiae. J Bacteriol (1998) 1.09

The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J Biol Chem (2000) 1.08

Prediction of secondary structural elements in glycerol-3-phosphate dehydrogenase by comparison with other dehydrogenases. Eur J Biochem (1980) 1.07

Products of mitochondrial protein synthesis in Neurospora crassa. Determination of equimolar amounts of three products in cytochrome oxidase on the basis of amino-acid analysis. Eur J Biochem (1973) 1.07

Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. Pharm Dev Technol (1998) 1.06

Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS PharmSci (2001) 1.06

Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol (2000) 1.04

Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. Pharm Dev Technol (1997) 1.02

Identification and subcellular location of talin in various cell types and tissues by means of [125I]vinculin overlay, immunoblotting and immunocytochemistry. Eur J Cell Biol (1988) 1.02

The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. Pharm Dev Technol (1998) 1.02

Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol (2013) 1.01

The Gist of literature on pediatric GIST: review of clinical presentation. J Pediatr Hematol Oncol (2009) 0.99

Theophylline serum protein binding in obstructive airways disease. Clin Pharmacol Ther (1981) 0.98

Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion (1982) 0.97

A safe and simple method for removal and replacement of a percutaneous endoscopic gastrostomy tube after "buried bumper syndrome". Endoscopy (2010) 0.95

Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues. J Clin Pharmacol (1999) 0.93

Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther (2000) 0.93

Comparison of long-term biocompability of PVDF and PP meshes. J Invest Surg (2011) 0.92

Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group. Clin Pharmacokinet (1997) 0.92

Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol (2003) 0.92

Pharmacological mechanism-based drug safety assessment and prediction. Clin Pharmacol Ther (2011) 0.92

[Feasibility and efficacy of cyberknife radiotherapy for lung cancer: early results]. Cancer Radiother (2008) 0.91

Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. AAPS PharmSciTech (2000) 0.91

The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res (1998) 0.91

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol (1995) 0.91

Acceptance of the 2009 A(H1N1) influenza vaccine among hospital workers in two French cancer centers. Vaccine (2010) 0.90

Cardiopulmonary exercise testing predicts postoperative outcome in patients undergoing gastric bypass surgery. Br J Anaesth (2012) 0.90

Primary lung sarcomas: long survivors obtained with iterative complete surgery. Lung Cancer (2001) 0.90

On the linkages between chromophore and protein in biliproteins, VII. Amino acid sequence in the chromophore regions of C-phycoerythrin from Pseudanabaena W 1173 and Phormidium persicinum. Hoppe Seylers Z Physiol Chem (1978) 0.90

Cytokine concentrations in sputum from patients with cystic fibrosis and their relation to eosinophil activity. Am J Respir Crit Care Med (1997) 0.90

Individual bioequivalence revisited. Clin Pharmacokinet (2001) 0.89

Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol (1994) 0.89

Influence of secretin on the course of acute experimental pancreatitis in rats. Digestion (1983) 0.89

[Acute appendicitis. Modern diagnostics--surgical ultrasound]. Chirurg (2009) 0.89

Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg (2007) 0.89

Improved micromethod for mezlocillin quantitation in serum and urine by high-pressure liquid chromatography. Antimicrob Agents Chemother (1984) 0.88

FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol (1999) 0.88

Effect of cholesterol content on antitumor activity and toxicity of liposome-encapsulated 1-beta-D-arabinofuranosylcytosine in vivo. Cancer Res (1980) 0.88

Esterase-17 (ES-17): characterization and genetic location on chromosome 9 of a bis-p-nitrophenyl phosphate-resistant esterase of the house mouse (Mus musculus). Biochem Genet (1983) 0.88

Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin Pharmacol Ther (2012) 0.88

Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol (1985) 0.87

Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther (1999) 0.87

Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors. Pharmacotherapy (1998) 0.87

[Guillain-Barré syndrome and non-Hodgkin's lymphoma. Report of one case and review of literature]. Rev Med Brux (2005) 0.86

Transporter-mediated drug-drug interactions. Clin Pharmacol Ther (2011) 0.86

In vivo drug-drug interaction studies--a survey of all new molecular entities approved from 1987 to 1997. Clin Pharmacol Ther (2000) 0.85

Chromatography on microbore columns. Methods Enzymol (1977) 0.85

[Therapy of rheumatic disease with a hydroxyethylsalicylate gel. Results of 2 clinical studies of effectiveness and bioavailability]. Fortschr Med (1995) 0.85

The "additional subunit" CF0II of the photosynthetic ATP-synthase and the thylakoid polypeptide, binding ferredoxin NADP reductase: are they different? Z Naturforsch C (1991) 0.85

Relative bioavailability of aspirin gum. J Pharm Sci (1981) 0.85

The course of pain is the same in alcohol- and nonalcohol-induced chronic pancreatitis. Pancreas (1995) 0.85

The need for education in pharmacogenomics: a regulatory perspective. Pharmacogenomics J (2005) 0.85

Unique properties of the large antigen of hepatitis delta virus. J Virol (1999) 0.85

[Topical treatment of soft tissue rheumatism and athletic injuries. Effectiveness and tolerance of a new ketoprofen gel]. Fortschr Med (1996) 0.85

Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies? Int J Clin Pharmacol Ther (2001) 0.84

Recovery of the pancreas after acute pancreatitis is not necessarily complete. Int J Pancreatol (1995) 0.84

Secretin-pancreozymin test (SPT) and endoscopic retrograde cholangiopancreatography (ERCP): both are necessary for diagnosing or excluding chronic pancreatitis. Pancreas (1996) 0.84

Combination of cisplatin-doxorubicin-cyclophosphamide in adenocarcinoma of unknown primary site: a phase II trial. Am J Clin Oncol (2001) 0.84

Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica (2000) 0.83

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer (2000) 0.83

Defining the maximum tolerated dose: investigator, academic, industry and regulatory perspectives. J Clin Pharmacol (1997) 0.83

Influence of buprenorphine on acute experimental pancreatitis. Res Exp Med (Berl) (1987) 0.83

Three years of promise, proposals, and progress on optimizing the benefit/risk of medicines: a commentary on the 3rd FDA-DIA-PWG-PhRMA-BIO pharmacogenomics workshop. Pharmacogenomics J (2006) 0.82

Variability in the bioavailability of phenytoin capsules in males and females. Pharm Res (2001) 0.82

Impact of pressure and gas type on adhesion formation and biomaterial integration in laparoscopy. Surg Endosc (2011) 0.82

Impact of mesh positioning on foreign body reaction and collagenous ingrowth in a rabbit model of open incisional hernia repair. Hernia (2009) 0.82

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report. Clin Pharmacol Ther (2001) 0.82

Pancreatic calcifications: no indicator of severe exocrine pancreatic insufficiency. Gastroenterology (1986) 0.82

Mesh migration into the esophageal wall after mesh hiatoplasty: comparison of two alloplastic materials. Surg Endosc (2007) 0.82

[The natural course of chronic pancreatitis--pain, exocrine and endocrine pancreatic insufficiency and prognosis of the disease]. Zentralbl Chir (1995) 0.81

Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology (2010) 0.81

Evaluation of tissue components in the peripheral nervous system using Sirius red staining and immunohistochemistry: a comparative study (human, pig, rat). J Neurosci Methods (2010) 0.81